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Abstract
Background: Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection in young children
in both the community and hospital setting.
Methods: The clinical presentation, patient and phylogenetic characteristicsof laboratory-confirmed cases of RSV, as
well as risk factors for nosocomial infectionat Red Cross War Memorial Children’s Hospital in Cape Town were
analysed. A multiplex PCR assay that detects 7 respiratory viruses was used to identify RSV nucleic acid on
respiratory specimens.
Results: A total of 226 children were studied, ages ranging between 1 week and 92.5 months (median: 2.8 months,
IQR: 1.3–6.3 months) and 51.8 % were males. The median duration of symptoms prior to diagnosis was 2 days
(IQR: 1–4 days). Nosocomial infections wereidentified in 22 (9.7 %) children. There were pre-existing medical
conditions in 113 (50.0 %) excluding HIV, most commonly prematurity (n = 58, 50.0 %) and congenital heart disease
(n = 34, 29.3 %). The commonest presenting symptoms were cough (196, 86.7 %), difficulty in breathing (115, 50.
9 %) and fever (91, 41.6 %).A case fatality rate of 0.9 % was recorded. RSV group A predominated (n = 181, 80.1 %)
while group B accounted for only 45 (19.9 %) of the infections. The prevalent genotypes were NA1 (n = 127,70.1 %),
ON1 (n = 45,24.9 %) and NA2 (n = 9,5.0 %) for group A while the only circulating RSV B genotype was BA4. There
was no significant difference in the genotype distribution between the nosocomial and community-acquired RSV
infections. Age ≥ 6 months was independently associated with nosocomial infection.
Conclusions: A large percentage of children with RSV infection had pre-existing conditions. Approximately one
tenth of the infections were nosocomial with age 6 months or older being a risk factor. Though both RSV groups
co-circulated during the season, group A was predominant and included the novel ON1 genotype. Continued
surveillance is necessary to identify prevalent and newly emerging genotypes ahead of vaccine development and
efficacy studies.
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Background
Respiratory syncytial virus (RSV) is an important cause
of bronchiolitis and pneumonia in infants and young
children [1]. Globally, it is estimated that RSV causes
over 30 million new acute lower respiratory tract infec-
tion (LRTI) episodes annually, resulting in more than 3.4
million hospital admissions and199,000 deaths in chil-
dren younger than 5 years of age [1]. One-third of RSV-
related deaths occur in the first year of life, with 96 % of
these deaths occurring in low-resource countries [1]. Re-
peated infections may occur throughout life as immunity
following the first RSV infectiondoes not protect against
subsequent infections [2]. The infection is spread mainly
by close or direct contact with infectious secretions or
after touching contaminated surfaces [3]. Risk factors
associated with RSV disease include prematurity, cardio-
pulmonary and immunosuppressive diseases [4]. Noso-
comial outbreaks of RSV, which usually coincide with
seasonal outbreaks, are a major hazard in paediatric
wards, especially in those individuals with increased risk
of RSV infection. Nosocomial outbreaks are associated
with prolonged hospitalisation and increased mortality
compared to community-acquired illness [5–7]. HIV-
infected children also experience prolonged shedding of
RSV [6].
RSV is classified into groups A and B based on reac-
tions with monoclonal antibodies against the fusion (F)
and attachment (G) glycoproteins [8]. Both groups co-
circulate within the community and health care institu-
tions and predominance of one over the other varies by
year and geographic location [9, 10]. Many genotypes
from each group have been described. New genotypes
are continuing to emerge while others are no longer
detectable [11, 12]. Although the predominant group
and overall patterns of circulating genotypes are distinct
for different communities [11],emerging RSV genotypes
are also thought to show global spread [13]. Different
genotypes may co-circulate within a season, with certain
genotypes dominating before being replaced with other
genotypes [14, 15]. There are conflicting reports on the
association of different groups and genotypes with sever-
ity of illness [16–19]. Ongoing surveillance of the clinical
and molecular epidemiology of RSV genotypesis import-
ant to characterise prevalent and emerging genotypes
that may impact on vaccine development.
The aims of the study were to determine the propor-
tion of RSV nosocomial infections among children test-
ing positive for RSV, describe clinical characteristics of
patients with the infection, phylogenetically classify the
genotypes causing nosocomial and community-acquired
infection, and determine risk factors associated with
nosocomial infection in children with acute LRTI, hospi-




The study took place at RCWMCH a tertiary referral
hospital affiliated to the University of Cape Town and
caring for children up to the age of 13 years. A retro-
spective cross-sectional study was conducted on patients
with confirmed LRTI and RSV who had been hospita-
lised between January and October 2012. These patients
were identified from the Division of Medical Virology
laboratory database. The time period of January to
October 2012 was chosen because the laboratory database
detected the first cases of RSV in January and the last
cases in October 2012.
Clinical data collection
Clinical information was extracted retrospectively from
hospital records, including demographic data, mode of in-
fection (community-acquired vs. nosocomial), underlying
medical conditions, potential risk factors for nosocomial
RSV infection and disease outcome. The information was
recorded on a standardised data collection form and an-
onymously entered into an Excel spreadsheet.
Case definitions
Nosocomial RSV infection was diagnosed in a child who
developed new symptoms and signs of LRTI at least
5 days after hospital admission and in whom RSV was
detected in respiratory secretions collected during the
new respiratory infection [20, 21].
Community-acquired RSV infection was diagnosed in
a child with an acute LRTI present at the time of
hospital admission or occurring withinor occurring
within less than 5 days of admission and in who RSV was
detected in respiratory secretions.
Acute LRTI was as per the attending clinicians’ diagno-
sis. A high-dependency or high-care unit is where special-
ist nursing care and monitoring of seriously ill patients is
provided with a higher level of care available than on
general wards but less than is given to patients in intensive
care [22].
HIV infection in children aged <18 months was diag-
nosed by HIV DNA PCR and confirmatory HIV RNA
PCR, and in children ≥18 months of age by HIV Rapid
test and confirmatory HIV enzyme-linked immunosor-
bant assay (ELISA). HIV exposed uninfected refers to in-
fants that are born to HIV positive women but tested
negative by HIV PCR.
Chest radiograph classification
Chest radiographs of the patients taken within 24 h of
diagnosis of acute LRTI due to RSV infection were ob-
tained. Antero-posterior and lateral images were viewed
in most instances. The radiological findings were cate-
gorised according to the World Health Organization’s
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standardised classification for interpreting chest radio-
graph findings for epidemiological studies: (1) primary
end-point consolidation or pleural effusion i.e. the pres-
ence of end-point consolidation or pleural effusion that
meets criteria for primary end-point, (2) other consolida-
tion or infiltrates i.e. the presence of other (non-end –
point) infiltrates, and (3) no consolidation, infiltrate or
effusion i.e. the absence of end point consolidation, other
infiltrate or pleural effusion [23]. The radiographs were
reported independently by 2 of the investigators (RO and
BE), without knowledge of the clinical information of each
patient. A consensus was reached for any images in which
there was a discrepancy.
Laboratory diagnosis of RSV infection, co-infections and
RSV phylogenetic analysis
A commercial multiplex PCR assay (Seeplex RV7, Seegene,
Seoul, South Korea) was used to screen for 7 respiratory
viruses (Influenza A, Influenza B, Metapneumovirus, RSV
A/B, Rhinovirus A, Parainfluenza 1/2/3, Adenovirus) on
nasopharyngeal aspirate or bronchoalveolar lavage speci-
mens. Bacterial and viral co-pathogens were identified on
blood, tracheal aspirate or urine specimens obtained at the
discretion of the attending clinicians. Diagnostic assays
were performed at the Medical Virology and Microbiology
Laboratories at Groote Schuur Hospital National Health
Laboratory Service. Viral complementary DNA (cDNA)
specimens generated during the performance of the diag-
nostic assay for all viral isolates were stored at -80 °C.
These stored specimens were used to characterise the
relatedness of the RSV isolates.
Viral phylogeny was determined by partial sequencing
of the RSV G envelope glycoprotein based on previously
published methodology [24]. PCR amplicons were se-
quenced using BigDye terminator chemistry and sequences
determined on an ABI 3130XL genetic analyzer (Applied
Biosystems, Carlsbad, USA). The phylogenetic analysis was
done by multiple RSV isolates sequence alignments using
BioEdit 7.09 (Ibis Biosciences, Carlsbad USA). Construc-
tion of neighbour-joining phylogenetic trees was com-
puted by using MEGA 4.1 (The Biodesign Institute,
Tempe, USA). Sequence differences were visualised
using highlighter nucleotide transition and transversion
plots (www.hiv.lanl.gov).
Analytical methods
Data were entered and analysed using SPSS 22. The
clinical information was analysed using conventional
parametric and non-parametric statistical methods. De-
mographic, clinical and laboratory variables were explored
using univariate analysis. Variables associated with noso-
comial infection were analyzed using a multivariable logis-
tic regression model. The level of significance was set
at p < 0.05.
Results
Two-hundred and twenty-six children with PCR-
confirmed RSV acute lower respiratory tract infection were
identified during the study period, January to October
2012. Figure 1 shows the monthly distribution of commu-
nity-acquired and nosocomial acute respiratory tract infec-
tion associated with RSV. Case detection peaked in May.
Characteristics of children with RSV infection
Table 1 shows the demographic characteristics and age
distribution of the children with RSV infection. The
median age of the children studied was 2.8 months (IQR:
1.3–6.3 months) and 160 (70.8 %) were less than 6 months
of age. Pre-existing conditions other than HIV infection
were present in 113 children (50.0 %). Table 2 shows the
characteristics disaggregated according to different age
groups. There were 117 males (51.8 %). A chest radio-
graph was obtained in 221 (97.8 %) of the cases and fea-
tures consistent with lower respiratory tract infection
were observed in 220 (97.4 %). HIV infection was con-
firmed in only 4 (1.8 %) children, 211 (83.4 %) were unin-
fected while the status of 11 (4.9 %) was unknown.
Clinical characteristics, management and outcome
The median duration of symptoms preceding hospital-
isation was 2 days (IQR: 1–4 days). As shown in Table 3,
the commonest presenting symptoms were cough 196
(86.7 %), difficulty in breathing (tight chest) 115 (50.9 %)
and fever 91 (41.6 %). Wheezing was present in 20 (8.8 %)
Table 1 Age and pre-existing conditions other than HIV infection
Parameter N = 226
Median age (Months) 2.8
IQR 1.3–6.3
Age group (months)
0 – <1 31 (13.7 %)
1- < 3 84 (37.2 %)
3- < 6 45 (19.9 %)
6 – <24 60 (26.5 %)
≥ 24 6 (2.7 %)
Pre-existing conditions other than HIV infection N = 113 (50.0 %)
Prematurity 58 (51.3 %)
Congenital heart disease 34 (30.1 %)
Chronic lung disease 20 (17.7 %)
Previous IPPV 17 (15.0 %)
Trisomy 21 13 (11.5 %)
Previous cardiac surgery 7 (6.2 %)
a Other conditions 7 (6.2 %)
a Other conditions: Gastro-oesophageal Reflux Disease (n = 1), Guillain-Barré
syndrome (n = 1), VATER (Vertebral defects, anal atresia, cardiac defects,
tracheo-esophageal fistula and renal anomalies) syndrome (1), cerebral palsy
(n = 2) and other chromosomal abnormalities (n = 2)
Oladokun et al. BMC Infectious Diseases  (2016) 16:236 Page 3 of 10
of the cases. With regards to the management of the pa-
tients, 170 (75.2 %) cases received supplemental oxygen,
89 (39.4 %) were admitted either in the intensive care or
high care units while 59 (26.1 %) required assisted ventila-
tion by continuous positive airway pressure (CPAP) or
mechanical ventilation. Antibiotics were instituted in 221
(97.8 %), but confirmed bacterial infection was detected in
only 24 (10.6 %) children. While 170 (75.2 %) were dis-
charged, 54 (23.9 %) were transferred to a primary or
secondary hospital for ongoing care. The median duration
of stay in RCWMCH was 5.0 days (Range 1–90 days).
Two patients died giving a mortality rate of 0.9 %.
The first death occurred in an 8.8 month old male, who
was HIV negative and hospitalised with community acquired
RSV infection and acute gastroenteritis but no pre-existing
condition. He also had adenovirus co-infection. He was
nursed in intensive care unit (ICU) and required intermittent
positive pressure ventilation (IPPV) but died as a conse-
quence of respiratory failure on day 3 of hospitalisation. He
had been infected with an RSV genotype BA4 isolate.
The second death occurred in a2.8 month old preterm
female who was HIV negative andhad community
acquired RSV infection. She was nursed in ICU and ven-
tilated. She died on day 38 of admission from respiratory
failure. She had been infected with a RSV ON1 genotype
isolate.
Co-pathogens during RSV-lower respiratory tract infection
Seventeen different viral, bacterial and fungal co-pathogens
were identified in 70 (31.1 %) children. The commonest
isolates were rhinovirus 22 (26.2 %), adenovirus 12
(14.3 %) and para-influenza virus 10 (11.9 %). Bacterial
pathogens accounted for 24 (28.6 %) of the isolates, in-
cluding 6 (7.1 %) isolated from blood cultures. The com-
monest bacterial isolates included Staphylococcus aureus 8
(9.5 %), Escherichia coli 2 (2.4 %) and Pseudomonas aeru-
ginosa 2 (2.4 %).
Genotype distribution and pattern of RSV infection
RSV A and RSV B accounted for 181 (80.1 %) and 45
(19.9 %) of the infections, respectively. There were no
mixed infections with both A and B groups. The preva-
lent genotypes were NA1 (n = 127, 70.1 %), ON1 (n = 45,
24.9 %) and NA2 (n = 9, 5.0 %) for groupA, while the
only circulating RSV B genotype was BA4. Age, gender,
need for assisted ventilation, HIV status and presence
of co-pathogens were not associated with the RSV
genotypes.
Table 2 Characteristics of children with RSV infection by age group
Age group (months)
Parameter 0 – <1 1– < 3 3– < 6 6 – < 24 ≥24 Total
N = 31(%) N = 84(%) N = 45(%) N = 60(%) N = 6(%) N = 226(%)
Gender
Male 17(54.8) 46 (54.8) 20 (17.1) 32 (53.3) 2(33.3) 117 (51.8)
Female 14 (45.2) 38 (45.2) 25 (55.6) 28 (46.7) 4 (66.7) 109 (48.2)
Chest X-ray conclusion
Primary end-point consolidation or pleural effusion 9 (29.0) 27 (32.1) 7 (15.6) 11 (18.3) 2 (33.3) 56 (24.8)
Other consolidation/infiltrate 21 (67.7) 56 (66.7) 36 (80.0) 47 (78.3) 4 (66.7) 164 (72.6)
No consolidation/infiltrate/effusion 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.7) 0 (0.0) 1 (0.4)
No X-ray 1 (3.2) 1 (1.2) 2 (4.4) 1 (1.7) 0 (0.0) 5 (2.2)
Weight-for-age Z- score
> +2 (overweight) 0 (0.0) 1 (1.2) 0 (0.0) 1 (1.7) 0 (0.0) 2 (0.9)
+ 2 to -2 (appropriate) 22 (71.0) 54 (64.3) 21 (46.7) 33 (55.0) 4 (66.7) 134 (59.3)
< -2 to -3 (moderately underweight) 4 (12.9) 16 (19.0) 8 (17.8) 12 (20.0) 1 (16.7) 41 (18.1)
< -3 (severely underweight) 5 (16.1) 13 (15.1) 16 (35.6) 14 (23.3) 1 (16.7) 49 (21.7)
HIV status
Unexposed uninfected 21 (67.7) 64 (76.2) 29 (64.4) 45 (76.7) 4 (66.7) 164 (72.6)
Exposed uninfected 8 (25.8) 18 (21.4) 14 (31.1) 7 (11.7) 0 (0.0) 47 (20.8)
Infected 1 (3.2) 0 (0.0) 1 (2.2) 1 (1.7) 1 (16.7) 4 (1.8)
Unknown 1 (3.2) 2 (2.4) 1 (2.2) 6 (10.0) 1 (16.7) 11 (4.8)
Pre-existing conditions other than HIV infection
Yes 9 (29.0) 30 (35.7 29 (64.4 39 (65.0 6 (100.0) 113(50)
No 22 (71.0) 54 (64.3) 16 (35.6) 21 (35.0) 0 (0.0) 113(50)
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The NA1 genotype predominated especially between the
months of March to June (Fig. 2), and was the predomin-
ant genotype implicated in both community-acquired and
nosocomial infections. There was no significant difference
in the genotype distribution between the nosocomial and
community-acquired RSV infections (Table 4).
Characteristics of patients requiring assisted ventilation
In univariate analysis, RSV infection with co-pathogens,
nosocomial infection, higher median band cell percentage
and lower median platelet concentration were significantly
associated with the need for assisted ventilation (Table 5).
Factors associated with nosocomial RSV infection
Factors significantly associated with nosocomial infec-
tion on univariate analysis included age 6 months or
older and pre-existing conditions. However, on multi-
variate analysis age 6 months or older was the only fac-
tor independently associated with nosocomial infection
with RSV (Table 6). The odds of nosocomial infection
was 3.35 times higher in infants and children aged
6 months or older, compared to younger infants (ad-
justed OR = 3.35 (1.20–9.36); p = 0.02).
Discussion
In our study of hospitalised children in Cape Town, the
RSV cases were recorded from January until October
with most cases occurring in May 2012. This is consist-
ent withdata from the severe acute respiratory infections
(SARIs) surveillance programme from South Africa
which showed that despite circulation throughout the
year, the RSV season in the southern hemisphere peaked
between February and May [14].
Table 3 Clinical and laboratory characteristics, management
and outcome of 226 patients with RSV infection
Parameter Number of patients (%)
Presenting symptom
Cough 196 (86.7)
Difficulty in breathing (tight chest) 115 (50.9)
Fever 91 (41.6)
Nasal congestion 67 (29.6)




Inflammatory and haematological markers
Median CRP (mg/L) 12.3
Median WCC (x 109/L) 11.1
Median percent band cell count 8.0
Median Haemoglobin concentration (g/dL) 11.0
Median platelet count (x 109/L) 410
Treatment
Supplemental oxygen 170 (75.2)
Bronchodilators 150 (66.4)
Assisted ventilation N = 59 (26.1)
CPAP 43 (19.0)
IPPV 16 (7.1)
Antibiotics N = 221 (97.8)
Intravenous 174 (78.7)
Oral 47 (21.3)
Presence of co-pathogens 70 (31.1)
Care level N = 89 (39.4)
ICU 47 (20.8)
High care 38 (16.8)
Both ICU and high care 4 (1.8)
Outcome
Discharged 170 (75.2)
Transferred to another hospital 54 (23.9)
Died 2 (0.9)
CPAP Continuous positive airway pressure, IPPV Intermittent Positive Pressure
Ventilation, ICU Intensive care unit, CRP C-reactive protein, WCC White cell count


























Fig. 1 Monthly distribution of community-acquired and nosocomial
acute lower respiratory tract infection associated with RSV
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Infants under 6 months of age constituted 71 % of the
cohort, which is consistent with a previous study from
Kenyain which 58 % of children with RSV were under
6 months of age [25]. In contrast, a study from
Indonesia reported the highest incidence of RSV among
children aged 6 to 24 months, with low incidence in in-
fants less than 6 months and no cases detected in those
under 3 months [26]. These differences may be partially
explained by the population-based design, rather than
being hospital based [27, 28]. However, another
population-based study carried out in the United States
found that the highest rate of hospitalisation was in in-
fants who were less than 1 month old [29]. The full ex-
planation for these age differences remain unclear.
In the study cohort, 50 % of the children had pre-
existing conditions other than HIV infection. Notable
underlying conditions were prematurity (51 %) and con-
genital heart disease (30 %). Other important conditions
were malnutrition and trisomy 21. Unlike the previous
study in South Africa carried out when paediatric HIV
exposure and infection prevalence was very high in hos-
pitalised children [6, 12], the present study recorded a
lower HIV exposure prevalence of 21 % and infection
prevalence of only 2 %. The low HIV infection preva-
lence is primarily due to reduced perinatal HIV trans-
mission resulting from more widely implemented
prevention of mother-to-child interventions in South
Africa [30]. Prematurity and other high risk conditions
however remain prevalent. Immunoprophylaxis may be
used in children with underlying conditions as no vac-
cines currently exist for RSV. Palivizumab has been
found to reduce by half the risk of hospitalisation due to
RSV infection in these high-risk infants and children,
but the high cost prohibits its use in most low- and
middle-income countries, including South Africa [31].
Cough was the commonest symptom which was re-
corded in 86 % of the children, followed by difficulty in
breathing (tight chest) in 51 % and fever in 42 %.
Wheeze was recorded in only 9 %. Though there was no
comparison of the clinical features between RSV positive
and RSV negative children in our study, the symptoms
were similar to the findings in a study from Pakistan
[32]. In that study, the most frequent clinical findings in
RSV cases were cough (99 %) and fever (91 %), though
wheezing was also present in 91 % of the cases. In the
Table 4 RSV genotypes in relation to nosocomial infection
RSV genotype Nosocomial infection Community acquired Total P value
n = 22 n = 204 N = 226 (% of total)
NA1 14 (63.6 %) 113 (55.4 %) 127 (56.2) 0.61
NA2 0 (0.0 %) 9 (4.4 %) 9 (4.0)
ON1 5 (22.7 %) 40 (19.6 %) 45 (19.9)
BA4 3 (13.6 %) 42 (20.6 %) 45 (19.9)
Table 5 Characteristics associated with need for assisted
ventilation
Characteristic Assisted ventilation No ventilation P-value
No % No %
Age
< 6 45 76.3 115 68.9 0.18
≥ 6 14 23.7 52 31.1
Gender
Male 32 54.2 85 50.9 0.39
Female 27 45.8 82 49.1
Pre-existing condition
Yes 29 25.7 84 74.3 0.88
No 30 26.5 83 73.5
Weight-for-age z score
Normal 33 24.6 101 75.4 0.54
Underweight 26 28.3 66 71.7
HIV status
Infected 2 50.0 2 50.0 0.28
Uninfected 57 25.7 165 74.3
Co-pathogen
Yes 32 54.2 38 22.8 <0.001
No 27 45.8 129 77.2
RSV subtype
A 49 83.1 132 79.0
B 10 16.9 35 21.0
Pattern of infection
Nosocomial 10 16.9 12 7.2 0.03
Community-acquired 49 83.1 155 92.8
Median CRP (mg/L) 19.95 11.8 0.08








Underweight: Weight-for-age z-score <2; CRP C-reactive protein, WCC White
cell count, Hb Haemoglobin
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study, clinical features were not statistically significantly
different when comparing RSV positive and negative
children presenting with acute respiratory infection [32].
In contrast, a study from Jordan that compared present-
ing symptoms as reported by parents in RSV-positive
and RSV-negative children, showed that RSV-positive
subjects were more likely to present with cough and
shortness of breath and less likely to present with fever,
decreased activity, diarrhoea, or vomiting [33]. The dif-
ferences recorded in the clinical symptoms of RSV may
partly explain the limited usefulness of clinical scores. It is
desirable to have a clinical index score for RSV disease in
order to reduce the use of antibiotics and unnecessary la-
boratory investigations as well as to facilitate institution of
appropriate infection control measures to reduce nosoco-
mial spread. A clinical score which will take into consider-
ation key bronchiolitis symptoms may be useful especially
in settings with limited laboratory support and cost. Bron-
chiolitis symptoms are however not specific to RSV and
unfortunately, lack of uniformity of clinical scores and lack
of useful association with outcomes have limited their use-
fulness. Most of the scoring systems have also not been
assessed for reliability and validity [34]. Oxygen saturation
in a scoring system would also perform poorly in a study
cohort of RSV cases such as ours with a high percentage
of congenital heart disease and chronic lung disease. It has
been suggested that repeat observations may rather pro-
vide a more valid overall assessment as the course of
bronchiolitis is variable and dynamic [35].
Co-pathogens were detected in 31 % of the patients with
RSV infection, most commonly rhinovirus (26 %), adeno-
virus (14 %) and para-influenza virus (12 %). It is note-
worthy that bacterial co-infectionswere only detected in
29 % of our RSV-positive cases while viral co-infections
accounted for 62 %. Unsurprisingly, most of these co-
pathogens were recovered from the respiratory tract.
Although, it may be difficult to determine the relative con-
tributions of the different pathogens that were identified
in causing disease or simply colonising the respiratory
tract, the presence of any co-pathogen was associated with
ventilation, an indicator of severe respiratory tract infec-
tion. A high percentage of the patients received antibiotics
which was consistent with WHO recommendations to
treat all children with pneumonia with antibiotics, to
reduce pneumonia-associated mortality [36].
Ten percent of the children in our cohort had
nosocomially-acquired RSV infection, similar to findings
reported by Madhi et al. [6]. A Canadian multicentre
Table 6 Risk factors for nosocomial RSV infection
Risk factor Nosocomial N = 22 n/n(%) Crude OR (95 % CI) p value Adjusted b OR (95 % CI) p value
Age
< 6 months 9/160(5.6) 1 1
≥ 6 months 13/66(19.7) 4.11 (1.66–10.18) 0.002 3.35 (1.20–9.36) 0.02
Gender
Male 9/117(7.7) 1 1
Female 13/109(11.9) 1.63 (0.67–3.97) 0.29 1.90 (0.69–5.24) 0.22
Weight-for-age z score
Appropriate 10/134(7.5) 1 1
Underweight 12/92(13) 1.86 (0.78–4.51) 0.17 1.55 (0.56–4.3) 0.40
Pre-existing conditions other than HIV infection
Yes 17/113(15) 1 1
No 5/113(4.4) 0.23 (0.09–0.74) 0.01 0.40 (0.13–1.27) 0.12
HIV status a
Unexposed uninfected 15/164(9.2) 1 1
Exposed uninfected 4/47(8.5) 0.93 (0.29–2.93) 0.89 1.26 (0.36–4.40) 0.72
Exposed infected 1/4(25.0) 3.31 (0.32–33.84) 0.31 4.31 (0.34–55.44) 0.26
RSV genotype
N A1 14/127(11.0) 1 1
NA2 0/9(0) NA NA
ON1 5/45(11.1) 1.01 (0.34–2.98) 0.34 0.84 (0.26–2.73) 0.77
BA4 3/45(6.7) 0.58 (0.16–2.11) 0.16 0.70 (0.18–2.81) 0.62
OR (95% CI) Odds ratio (95 % confidence interval)
a HIV status not known in 11; n/n = stratum specific prevalence. NA = Not applicable
b Model adjusted for nutritional status, HIV status, age, sex, genotype and pre-existing conditions
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study reported a lower prevalence of 6 % [37]. Nosoco-
mial prevalence rates of more than 20 % have been doc-
umented in studies investigating RSV infection in infant,
ICU and haematology-oncology units [7, 38, 39]. In the
present study, logistic regression analysis showed that
the adjusted odds of developing nosocomial infection
was more than three-fold greater in children aged6
months or older, compared to younger infants. It is pos-
sible that younger children acquire RSV in the commu-
nity due to the intense transmission and those older
represent a specific group of patients in ourhospital. Hall
et al reported that the risk of nosocomial infection could
not be related to age or underlying disease but rather to
the duration of hospital stay [4]. In the study by Madhi
et al, nosocomial infection was found to be greater in
children with risk factors which included prematurity,
congenital heart disease and chronic lung disease [6].
Differences between studies is likely to continue as a
result of variations in design, study location and study
population. Nosocomial infections should be anticipated
when there is a community outbreak and preparations
made to prevent in-patients from acquiring the disease
during the course of their hospitalisation. Cheng et al.
have advocated for regular surveillance of the shedding
of virus and confirmation of viral clearance before dis-
continuation of infection control measures in order to
prevent further outbreaks in other patients [40]. Another
important consideration which is often overlooked is the
role of staff in the spread of RSV infection. About 40 %
of medical personnel in an infant ward in one study were
shown to have acquired the virus during a nosocomial
outbreak and appeared to play a major role as vectors for
transmission in the ward. [35] Staff may also continue to
be infected from close contact with ill infants or contami-
nated secretions [41].
RSV A and B groups co-circulated during the 2012
season, although groupA predominated (80 %). Three
group A genotypes (NA1, NA2 and ON1) were detected
with NA1 predominating (70 %) whereas only one group
B genotype (BA4) was detected. The ON1 genotype
though first isolated in Canada in 2011 has since been
isolated in other settings, including RCWMCH [42]. The
ON1 strain was reported to have spread and nearly re-
placed other RSV A strains in subsequent epidemic sea-
sons in central Italy and Cyprus [13]. The ON1 genotype
already appears to have become diversified as variants
distinct from the original viruses were found among
children admitted to a rural hospital in Kenya during
2012 [43].
A total of 45 ON1 isolates were reported in the
present study. A previous study described the first eight
ON1 isolates identified at our hospital [42]. The present
study showed that the genotype occurred throughout
the RSV season and there was no significant difference
in its distribution between nosocomial and community-
acquired infection. In contrast to Panayiotou et al who
reported that the mildest illness was associated with the
novel ON1 genotype compared to infections with geno-
types GA2 and BA (RSV B) [27], no differences were
recorded in the pattern of infection caused by individual
RSV groups or genotypes in our study. As the epidemio-
logic and pathophysiologic characteristics of RSV suggest
that there is potential for a different type of vaccine for
different target populations [43], the clinical and mo-
lecular epidemiology of RSV strains should be monitored
to identify new and emerging genotypes.
As with many retrospective studies, some variables
could not be analysed as a result of either incomplete-
ness or absence of data. For example, there was no infor-
mation on breastfeeding or exposure to cigarette smoke
in the patient records, and HIV results were not avail-
able for some children. The study was limited by being a
single centre, single season and the lack of a control
group. The convenience sampling method utilised in this
study may have inadvertently selected nosocomial cases.
Furthermore, the small number of nosocomial cases did
not allow for a more rigorous exploration of associa-
tions. As the host and viral factors associated with RSV
disease are highly dynamic, adequately powered pro-
spective multi-centre studies are required to address
these questions, explore the risk factors associated with
nosocomial infection in our setting comprehensively,
and unravel more facts about this complex virus infec-
tion in our setting.
Conclusions
RSV lower respiratory tract infection at RCWMCH has
been characterised with a large percentage of children
having pre-existing conditions. The majority of children
presented with cough and difficulty in breathing. Approxi-
mately one tenth of the RSV infections were nosocomial
with age 6 months or older a risk factor for nosocomial
acquisition. Though both RSV groups co-circulated during
the season, group A was predominant, and three different
A genotypes were documented including the novel ON1
genotype, first reported in Canada in 2011. Continued
surveillance of the clinical epidemiology and phylogeny of
RSV strains is important for vaccine development.
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